Prostate Cell News Volume 8.35 | Sep 15 2017

TOP STORY

Dysregulation of Spliceosome Gene Expression in Advanced Prostate Cancer by RNA-Binding Protein PSF

Proline splicing factor (PSF) stabilized and activated key long noncoding RNAs and AR-regulated gene expressions in prostate cancer cells. [Proc Natl Acad Sci USA] Abstract

(Ranked by impact factor of the journal)

Discovery of Peptide Drug Carrier Candidates for Targeted Multi-Drug Delivery into Prostate Cancer Cells

Investigators describe the use of strict criteria to isolate novel prostate cancer cell targeting peptides that specifically deliver drugs into target cells. Phage from a library displaying 7mer peptides were exposed to PC-3 cells and only internalized phage were recovered. [Cancer Lett] Abstract

Silencing of BACH1 Inhibits Invasion and Migration of Prostate Cancer Cells by Altering Metastasis-Related Gene Expression

Scientists found that the expression of BACH1 mRNA and protein in prostate cancer tissues was significantly higher than in matched normal prostate tissues. In addition, DU145 and LNCaP cells exhibited 4.25-fold and 3.45-fold higher levels of BACH1 compared to HFF cell line. [Artif Cells Nanomed Biotechnol] Abstract

Multi-Scale Mechanical Characterization of Prostate Cancer Cell Lines: Relevant Biological Markers to Evaluate the Cell Metastatic Potential

Researchers compared nano-mechanical properties of non-tumoral and highly aggressive metastatic prostate cell lines both on cell aggregates, single cells, and membrane lipids. [Biochim Biophys Acta] Abstract

Semaphorin 3 C Drives Epithelial-to-Mesenchymal Transition, Invasiveness, and Stem-Like Characteristics in Prostate Cells

Researchers showed that ectopic expression of semaphorin 3 C (SEMA3C) in RWPE-1 promotes the upregulation of epithelial-to-mesenchymal transition and stem markers, heightened sphere-formation, and cell plasticity. In addition, they showed that SEMA3C promotes migration and invasion in vitro and cell dissemination in vivo. [Sci Rep] Full Article

CYP17A1-Independent Production of the Neurosteroid-Derived 5α-Pregnan-3β,6α-diol-20-one in Androgen-Responsive Prostate Cancer Cell Lines under Serum Starvation and Inhibition by Abiraterone

Scientists demonstrated the CYP17A1-independent formation of 5α-pregnan-3β,6α-diol-20-one by androgen-responsive prostate cancer cells under serum starvation and its inhibition by abiraterone. [J Steroid Biochem Mol Biol] Abstract

Somatostatin Receptor Subtype 1 as a Potential Diagnostic Marker and Therapeutic Target in Prostate Cancer

Researchers found that somatostatin receptor subtype 1 is overexpressed in multiple cohorts of prostate cancer samples, as compared with normal prostate tissues, wherein it correlates with androgen receptor expression, and appears to be associated with aggressiveness. [Prostate] Abstract

The Protein Kinase C Super-Family Member PKN Is Regulated by mTOR and Influences Differentiation during Prostate Cancer Progression

Investigators focused on the PKN kinase family members, which underwent activation in response to phosphoinositide-3 kinase signaling, showed expression changes in prostate cancer, and contributed to cell motility pathways in cancer cells. [Prostate] Abstract

Effects of Tumor Necrosis Factor α upon the Metabolism of the Endocannabinoid Anandamide in Prostate Cancer Cells

Researchers investigated whether treatment of DU145 human prostate cancer cells affects anandamide (AEA) catabolic pathways. Additionally, they investigated whether cyclooxygenase-2 can regulate the uptake of AEA into cells. [PLoS One] Full Article

Treatment with the WNT5A-Mimicking Peptide Foxy-5 Effectively Reduces the Metastatic Spread of WNT5A-Low Prostate Cancer Cells in an Orthotopic Mouse Model

Researchers provide evidence that Foxy-5 significantly inhibited the initial metastatic dissemination of tumor cells to regional and distal lymph nodes by 90% and 75%, respectively. This effect was seen only with the WNT5A-low DU145 cells and not with the WNT5A-high PC3 cells. [PLoS One] Full Article

Androgen-Independent LNCaP Cells Are a Subline of LNCaP Cells with a More Aggressive Phenotype and Androgen Suppresses Their Growth by Inducing Cell Cycle Arrest at the G1 Phase

To mimic the traits of clinical prostate cancer progression in vitro, the authors investigated the alterations in the cell biological characteristics in androgen-independent LNCaP cells compared with LNCaP cells. [Int J Mol Med] Abstract

WNT Signaling in Prostate Cancer

Genome sequencing and gene expression analyses of prostate tumors have highlighted the potential importance of genetic and epigenetic changes observed in WNT signaling pathway components in prostate tumors — particularly in the development of castration-resistant prostate cancer. [Nat Rev Urol] Abstract

Extracellular Vesicles for Personalized Therapy Decision Support in Advanced Metastatic Cancers and Its Potential Impact for Prostate Cancer

Extracellular vesicles can potentially be utilized as biomarkers to provide accurate genotypic and phenotypic information for advanced prostate cancer, where new strategies to design a more personalized therapy is currently the focus of considerable investigation. [Prostate] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Pfizer and Astellas Announce Positive Top-Line Results from Phase III Prosper Trial of XTANDI (Enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Pfizer Inc. and Astellas Pharma Inc. announced that the Phase III PROSPER trial evaluating XTANDI^® plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer met its primary endpoint of improved metastasis-free survival. [Pfizer Inc.] Press Release

Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA^® (Abiraterone Acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer

Janssen Biotech, Inc. announced the submission of a supplemental New Drug Application to the FDA seeking to expand the indication of ZYTIGA^® in combination with prednisone and androgen deprivation therapy to include treatment of patients with high-risk metastatic hormone naïve prostate cancer or newly diagnosed, high-risk metastatic hormone sensitive prostate cancer. [Janssen Biotech, Inc.] Press Release

U.S. House Approves 2018 Spending Bills, but Process Far from Finished

The U.S. House of Representatives took a major step toward setting federal science budgets for the 2018 fiscal year. But Congress is still far from the finish line, and final spending levels aren’t likely to be finalized until late this year at the earliest. [ScienceInsider] Editorial

After Uproar, U.K. Parliament’s Science Committee Now Has a Female Member

The House of Commons Science and Technology Committee tweeted that it was “pleased to announced our membership has been confirmed.” Parliamentary committees had been dissolved after the recent U.K. election, and now the panel was rolling out its new contingent of lawmakers. The only problem: All eight of the mostly smiling faces belonged to men. [ScienceInsider] Editorial

NEW 18^th Annual Meeting of the Society of Urologic Oncology
November 29-December 1, 2017
Washington, D.C., United States

Visit our events page to see a complete list of events in the community.

NEW Researcher – Cancer Biology (University of Cincinnati)

Postdoctoral Fellow – Prostate Disease Research (The Henry M. Jackson Foundation for the Advancement of Military Medicine)

Research Assistant – Prostate Cancer (University College Dublin)

Postdoctoral Position – Molecular Imaging for Therapy Assessment in Prostate Cancer (Technische Universität München)

Postdoctoral Scientist – Prostate Cancer (Medical Research Council Laboratory of Molecular Biology)

Postdoctoral Position – Prostate Cancer (Moffitt Cancer Center)

Postdoctoral Fellowship – Translational Cancer Disparities Research (Duke Cancer Institute)

Postdoctoral Research Associate – Prostate Cancer (University of South Carolina)

Postdoctoral Position – Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine)

Postdoctoral Fellow – Drug Discovery (Vancouver Prostate Centre)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.